Disitamab Vedotin Plus Gemcitabine Shows Promise as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer
A phase 2 trial reports notable pCR rates and manageable toxicity for Disitamab Vedotin plus gemcitabine in HER2-positive MIBC patients.